LearnGlossaryMarketStocksSuperinvestorsSign in

IMNM

Immunome, Inc.

Healthcare · $2.0B market cap

Verdict

We can't put a fair value on IMNM right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth17.5% a year✓
Sales growth-29.6% a year✗
Free cash flow growth—?
Return on invested capital-57.2%✗

Follow IMNM

Track it on your watchlist and see the full analysis. Free.

Create a free account

About Immunome, Inc.

Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works